BDSI:NSD-BioDelivery Sciences International Inc (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSD

Last Closing Price

USD 5.59

Change

0.00 (0.00)%

Market Cap

USD 0.58B

Avg Analyst Target

USD 5.60 (+0.18%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


BioDelivery Sciences International Inc (BDSI) Stock Analysis:
Based on the BioDelivery Sciences International Inc stock forecasts from 4 analysts, the average analyst target price for BioDelivery Sciences International Inc is USD 5.60 over the next 12 months. BioDelivery Sciences International Inc’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of BioDelivery Sciences International Inc is Very Bullish, which is based on 3 positive signals and 0 negative signals. At the last closing, BioDelivery Sciences International Inc’s stock price was USD 5.59. BioDelivery Sciences International Inc’s stock price has changed by +0.00% over the past week, +0.00% over the past month and +54.85% over the last year.

About

BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioEr ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-18 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MYL Mylan N.V

N/A

USD8.59B 30.73 11.86
NBIX Neurocrine Biosciences Inc

-0.85 (-0.99%)

USD8.20B 93.26 60.75
APHA Tilray, Inc

N/A

USD6.86B 60.60 454.68
MNTA Momenta Pharmaceuticals, Inc

N/A

USD6.24B N/A N/A
ITCI Intra-Cellular Therapies Inc

-0.91 (-1.53%)

USD5.56B N/A N/A
PCRX Pacira BioSciences Inc

-2.17 (-3.41%)

USD2.89B 69.11 26.46
CGC Canopy Growth Corporation

-0.30 (-5.09%)

USD2.33B N/A N/A
TLRY Tilray Inc

-0.35 (-6.81%)

USD2.26B 47.29 N/A
HCM HUTCHMED (China) Limited

-1.59 (-15.14%)

USD1.82B 17.69 N/A
IRWD Ironwood Pharmaceuticals Inc

-0.24 (-2.06%)

USD1.79B 3.63 7.08

ETFs Containing BDSI

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 80.32% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 80.32% N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain 53.57% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 53.57% N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain 128.16% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 128.16% N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 19.08% 78% C+ 72% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 19.08% 78% C+ 71% C-
Risk Return Profile  
Volatility (Standard Deviation) 46.13% 54% F 33% F
Risk Adjusted Return 41.36% 87% B+ 67% D+
Market Capitalization 0.58B N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 6.82 N/A N/A N/A N/A
Price/Book Ratio 3.07 N/A N/A N/A N/A
Price / Cash Flow Ratio 14.06 N/A N/A N/A N/A
EV/EBITDA 11.71 N/A N/A N/A N/A
Management Effectiveness  
Return on Equity 57.33% N/A N/A N/A N/A
Return on Invested Capital 42.63% N/A N/A N/A N/A
Return on Assets 8.22% N/A N/A N/A N/A
Debt to Equity Ratio 28.84% N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 0.77 N/A N/A N/A N/A
Short Percent 4.60% N/A N/A N/A N/A
Beta 0.56 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:

There is nothing we particularly dislike